Results From A Phase I Study Of Amg 160

Results from a phase I study of AMG 160

European Association of Urology

AMG 160: immunotherapy for mCRPC

Initial results from Phase I/II Study of ARV-766 in mCRPC

Results from Phase I/II study of DS-7300a in advanced solid tumors

AMG 160: A PSMA-targeted, bispecific T-cell engager immune therapy for mCRPC

Phase I study of ATR inhibitor M1774 in patients with solid tumors

Enzalutamide for Biochemically Recurrent Prostate Cancer | NEJM

Expert Discusses Toxicity Results in CARD Study

Results of a phase 1 study of THR-149 for the treatment of DME

Study 1100 Phase I Results Webinar

Results of a Phase II Study of LHRH Therapy in High-Risk Prostate Cancer

Targeted Oncology

”What is the RTIRE clinical trial aiming to achieve?”

Doctor Grew Explains Cancer

ASCO® 2024 Insights: Dr. Daniel Petrylak on ARV-766

Yale Cancer Center

Phase I study results of M7824 for patients with HPV associated cancers

PROpel trial

European Association of Urology

The PROpel clinical trial exploring olaparib plus abiraterone in mCRPC

ESMO Expert Report on combination therapy in advanced prostate cancer @ ASCO GU 2022

European Society for Medical Oncology (ESMO)

The #RTIRE Trial is now recruiting patients with intermediate-risk prostate cancer.

Doctor Grew Explains Cancer

New Study Results: Prostate Cancer Part 1

Prostate Cancer - New Study Results (Part 2)